CAR-T cell therapy has transformed the treatment of several haematological malignancies, but its impact in solid tumours has remained frustratingly limited. Now, a new generation of in vivo CAR-T cell technologies promises to remove some of the biggest practical barriers associated with conventional cell therapy.

Cell and gene therapies are transforming the pharmaceutical industry, but commercial success requires coordinated planning across manufacturing, regulation, market access, reimbursement, supply chains, patient identification, and long-term value demonstration.

Breast cancer treatment is shifting from conventional chemotherapy toward targeted therapies, antibody-drug conjugates and biomarker-driven combinations, creating new opportunities for precision oncology and pharmaceutical innovation.

In the ESR1-mutated subgroup of EMBER-3, adding imlunestrant plus abemaciclib doubled median progression-free survival from 5.5 to 11.1 months, with a hazard ratio of 0.53. The approval therefore establishes another biomarker-defined treatment option for ER-positive/HER2-negative metastatic breast cancer after endocrine progression and further strengthens the clinical importance of identifying ESR1 mutations during the course of disease.

The International Myeloma Foundation's medical editorial team has compiled a comprehensive clinical update covering multiple myeloma research published in August-September 2026, reviewed by Dr. Joseph Mikhael. The update addresses diagnosis, risk stratification, and management of both multiple myeloma and smoldering multiple myeloma (SMM). Multiple myeloma diagnosis requires ≥10% clonal bone marrow plasma cells or biopsy-proven plasmacytoma with at least one myeloma-defining event, including CRAB features or biomarkers such as ≥60% clonal plasma cells, serum free light chain ratio ≥100, or >1 focal lesion on MRI. Current treatment incorporates anti-CD38 monoclonal antibodies (daratumumab or isatuximab), bortezomib, lenalidomide, and dexamethasone, potentially followed by autologous stem cell transplantation. Relapsed disease management includes CAR-T cell therapy, bispecific antibodies, and belantamab mafodotin. Notably, the AQUILA randomized trial demonstrated that three years of daratumumab in high-risk SMM patients significantly delayed progression to active myeloma and improved survival, achieving 63.1% versus 40.8% five-year progression-free survival compared with active monitoring alone.

This open-access review examines nucleic acid-based antimicrobial strategies as emerging therapeutic approaches against drug-resistant Staphylococcus aureus, a major public health threat. The article comprehensively analyzes the mechanisms of action underlying nucleic acid therapeutics, including antisense oligonucleotides, small interfering RNAs, and aptamers, which target bacterial pathogenicity factors and resistance mechanisms. The review critically evaluates various delivery approaches essential for effective antimicrobial efficacy, such as nanoparticle carriers, liposomes, and conjugation strategies that enhance bacterial cell penetration and bioavailability. Published in Infectious Diseases and Therapy in September 2026, this work addresses the growing clinical challenge of methicillin-resistant S. aureus and other resistant strains by exploring how nucleic acid therapeutics can modulate virulence genes and resistance pathways. The significance lies in identifying alternative treatment paradigms beyond conventional antibiotics, offering potential solutions to antimicrobial resistance while reducing selective pressure. This comprehensive analysis provides valuable insights for researchers and clinicians developing next-generation therapeutic options for difficult-to-treat staphylococcal infections.

Genentech announced positive results from its Phase III evERA trial evaluating giredestrant, an oral estrogen receptor degrader, in combination therapy for estrogen receptor-positive advanced breast cancer. The study demonstrated that giredestrant significantly improved progression-free survival compared to standard treatment, marking an important advancement in hormone-positive breast cancer management. These findings were published in The New England Journal of Medicine, underscoring their clinical significance. Giredestrant represents a novel therapeutic approach by degrading estrogen receptors rather than simply blocking them, offering potential benefits for patients with advanced ER-positive disease who may have limited options. The evERA trial data support giredestrant's role as a meaningful treatment option, potentially expanding the therapeutic landscape for this common breast cancer subtype. This development is particularly relevant for oncology stakeholders, as it demonstrates continued innovation in precision medicine for hormone-dependent cancers and may influence treatment guidelines and clinical practice patterns for ER-positive advanced breast cancer management.

Personalized neoantigen vaccines represent an emerging precision oncology approach that harnesses patient-specific immunotherapy by targeting tumor-restricted antigens derived from genomic and transcriptomic alterations, including single-nucleotide variants, insertions, deletions, frameshifts, gene fusions, and aberrant splicing events. Early clinical studies have demonstrated manufacturing feasibility and immunogenicity, while randomized phase 2b evidence in resected melanoma patients has shown promising clinical activity signals requiring confirmation in larger trials. However, clinical development remains concentrated in high-income academic centers, prompting concerns about equitable implementation across Southeast Asia. This review examines published clinical evidence and health-system capacity across the eleven ASEAN member states, revealing heterogeneous regional capabilities. While several countries possess national genomic programs and tertiary molecular services, routine nationwide availability, public reimbursement, and equitable geographic access remain inadequately characterized. Critical implementation barriers include access to clinical-grade tumor-normal sequencing, bioinformatics expertise, patient-specific GMP manufacturing, and temperature-controlled distribution. Current immunopeptidomic training datasets demonstrate uneven HLA coverage across Southeast Asian populations. The authors propose a staged hub-and-spoke model linking clinical centers with regional GMP facilities to support prospective implementation studies, emphasizing that whether these vaccines reduce or widen existing cancer inequities depends on evidence-based patient selection, health-system investment, and sustainable financing.

Following successful negotiations, the Cell and Gene Therapy Access Model has established outcomes-based agreements (OBAs) between the Centers for Medicare & Medicaid Services and two gene therapy manufacturers—Genetix Biotherapeutics Inc. and Vertex Pharmaceuticals Incorporated—for treating severe sickle cell disease. Currently, 32 states plus the District of Columbia and Puerto Rico, collectively representing 84% of Medicaid beneficiaries with sickle cell disease, participate in the model. Seven participating states and the District of Columbia received Cooperative Agreement awards beginning August 1, 2025. Under OBAs, payment to manufacturers is tied to patients' health outcomes over defined periods; if therapies underperform expectations, manufacturers reimburse payers proportionally. This approach eliminates the need for individual state-level negotiations by enabling CMS to negotiate multi-state agreements while managing financial reconciliation, clinical outcome measures, and performance evaluation. The model's significance lies in improving access to expensive gene therapies while managing financial risk through performance accountability, ultimately benefiting Medicaid beneficiaries seeking life-changing treatments.

This systematic review and network meta-analysis evaluated the efficacy and cost-effectiveness of first-line immune checkpoint inhibitors combined with targeted therapy for advanced renal cell carcinoma in the Chinese healthcare context. Researchers analyzed seven Phase III randomized controlled trials encompassing 4,973 patients, comparing ICI-targeted combinations against sunitinib using network meta-analysis to assess progression-free survival and overall survival outcomes. A partitioned survival model was subsequently developed to conduct cost-effectiveness analysis over a 20-year horizon. Results demonstrated that pembrolizumab plus lenvatinib ranked highest for progression-free survival, while toripalimab plus axitinib achieved superior overall survival outcomes and the lowest incremental cost-effectiveness ratio at $62,204.37 per quality-adjusted life-year. However, all evaluated regimens exceeded the willingness-to-pay threshold of $40,332.35 per quality-adjusted life-year established for the Chinese healthcare system. These findings provide critical insights for healthcare policy makers and clinicians regarding the clinical benefits and economic implications of combining immune checkpoint inhibitors with targeted therapies in treating advanced renal cell carcinoma.

Pancreatic ductal adenocarcinoma (PDAC) remains one of oncology's most lethal cancers, with only 13.7% five-year survival rates and even grimmer outcomes in previously treated metastatic settings, where median overall survival is five to seven months. Despite KRAS mutations driving over 90% of pancreatic cancers for decades, the protein remained undruggable until recently due to its lack of well-defined pockets amenable to small-molecule inhibitors. While sotorasib and adagrasib, approved in 2021 and 2022 respectively, represented landmark breakthroughs by targeting the G12C mutation, this variant accounts for only 1-2% of PDAC cases. More prevalent mutations include G12D (40%), G12V (30%), and G12R (20%), necessitating alternative approaches. Daraxonrasib, a pan-RAS inhibitor, addresses this gap by targeting mutant and wild-type KRAS, HRAS, and NRAS isoforms in their active state. The drug forms a complex with cyclophilin A upon cellular entry, enabling high affinity binding to active RAS and overcoming previously insurmountable barriers. This innovation could transform treatment for the majority of PDAC patients currently lacking targeted options.

Allogeneic CAR-T cell therapy represents a significant advancement in treating T-cell malignancies, offering substantial scalability advantages over autologous approaches. Unlike autologous CAR-T therapies that require patient-specific cell engineering, allogeneic CAR-T utilizes donor-derived cells that can be manufactured at scale from a single source, dramatically reducing production time and costs while increasing accessibility. The primary challenge involves managing graft-versus-host disease (GVHD), a potentially severe complication arising when donor immune cells attack recipient tissues. Recent developments have focused on engineering strategies to mitigate GVHD risk while preserving the therapeutic anti-tumor effects. By implementing off-the-shelf manufacturing protocols and refined cell engineering techniques, developers can produce consistent, high-quality allogeneic CAR-T products suitable for broader patient populations. This scalability potential positions allogeneic CAR-T as a transformative approach in oncology, particularly for treating T-cell malignancies where rapid, standardized treatment deployment is critical. The technology's commercial viability depends on successfully balancing safety profiles with manufacturing efficiency.

The Cell and Gene Therapy (CGT) Access Model represents a groundbreaking federal initiative designed to expand access to innovative treatments for rare and severe diseases through outcomes-based agreements (OBAs) negotiated by the Centers for Medicare & Medicaid Services on behalf of state Medicaid agencies. This multi-year, voluntary model marks the first time the federal government has engaged in such negotiations with CGT manufacturers. The initial focus targets gene therapy treatments for sickle cell disease, a genetic blood disorder affecting Medicaid beneficiaries. States and manufacturers entered the program through a Request for Application process, with participation beginning between January 2025 and January 2026. The model aims to increase patient access to potentially transformative treatments while improving health outcomes and reducing costs to state Medicaid programs. Recognizing that gene therapy for sickle cell disease requires extended inpatient hospital stays and myeloablative chemotherapy that causes infertility, the model mandates participating manufacturers cover fertility preservation services. This comprehensive approach addresses both treatment access and critical patient support needs, with potential expansion to additional disease conditions in the future.

Chimeric antigen receptor (CAR) T-cell therapy has traditionally been accessible only through tertiary academic centers, creating significant barriers for patients in community settings. At the Community Oncology Alliance Payer Exchange & Innovation Summit, payer, provider, and network leaders convened to address this gap and establish pathways for expanding CAR T access to community oncology practices. The panel, moderated by Kiana Mehring from Florida Cancer Specialists & Research Institute, featured Anthony Bonagura from Optum, Aaron Lyss from OneOncology, and Ameet Patel from FCSRI. Participants identified three key success metrics: clinical outcomes matching those at academic centers, faster and improved patient access, and manageable financial burden for community practices. A critical innovation discussed was "brain-to-vein" time—the period from initial diagnosis to cellular therapy administration—where delays cause approximately 20 to 25 percent of patients to become ineligible. Panelists emphasized that success requires balancing diverse stakeholder expectations, including patient preferences, employer cost concerns, and the unrecognized work of care navigators and coordinators. This collaborative effort signals industry recognition that decentralizing CAR T access is essential for equitable patient care delivery.

Clinical trials have always been known to be executed in medical facilities. When the Covid-19 pandemic struck in 2020, much devastation occurred. The pandemic put a pause on many operations, including clinical trials. Clinical researchers needed to find a way to continue. This was done so by implementing a new upcoming way of research, decentralized clinical trials; Decentralized clinical trials are also referred to as DCT’s. The purpose of a DCT is to remove in-person contact between the study team and the patients/subjects.

BioNTech and Genentech have terminated the Phase 2 BNT122-01 trial of autogene cevumeran, a personalized mRNA cancer vaccine, after an independent monitoring board identified a survival imbalance between treatment groups. The trial enrolled approximately 327 patients with Stage II high-risk or Stage III colorectal cancer who had undergone surgery but retained circulating tumor DNA, indicating residual microscopic disease. The vaccine was administered as monotherapy without checkpoint inhibitor combination, compared against watchful waiting, the current standard of care. While the monitoring board detected more deaths in the vaccine arm and found no new safety signals, this represents a meaningful negative result given the trial's rigorous design testing whether individualized mRNA immunotherapy could work as standalone adjuvant treatment. Colorectal cancer presents a particularly challenging target, characterized as a cold tumor with an immunosuppressive microenvironment and historically poor immunotherapy responsiveness. The trial had already crossed its futility boundary in October 2025 before this termination decision, suggesting limited benefit prospects were evident prior to the survival imbalance identification.

Decentralized clinical trials (DCTs) offer promising solutions to barriers that prevent cancer patients from participating in research, particularly those in rural and medically underserved communities. The ACCC's Advancing Decentralized Clinical Trials in the Community Setting Roundtable Series explored how remote consent, telehealth, local laboratory and imaging services, digital health technologies, and mobile health professionals can improve access. However, successful implementation requires more than technology adoption—it demands practical workflows, clear oversight structures, engaged sponsors, prepared staff, and organizational cultures supporting innovation. A critical insight emerged: distance equals disparity. Geographic distance creates substantial obstacles to both routine oncology care and trial participation, with surveys showing approximately 89-90% of rural respondents unaware of clinical trials. The roundtable emphasized that meaningful access requires comprehensive community engagement strategies, including outreach, community advisory boards, culturally responsive recruitment materials, and patient representation in trial-review processes. These foundational efforts to build awareness and trust must occur well before patients need treatment options, recognizing that patients should never encounter clinical trials for the first time during urgent care situations. Sustainable decentralization demands equity-focused planning and community-centered approaches.

Personalized cancer vaccines represent a promising evolution in immunotherapy, moving beyond earlier approaches that targeted shared tumor-associated antigens with limited clinical success. These new vaccines sequence individual tumors to identify mutation-derived neoantigens—unique cancer-specific targets invisible to immune tolerance mechanisms—and create patient-specific formulations. Recent clinical progress demonstrates neoantigen-specific immune responses across melanoma, pancreatic cancer, and renal cell carcinoma. A significant breakthrough occurred in August 2026 when the phase III INTerpath-001 trial showed intismeran autogene combined with pembrolizumab met its primary endpoint of recurrence-free survival and key secondary endpoint of distant metastasis-free survival in resected high-risk melanoma patients. The fundamental advantage of this approach lies in exploiting somatic mutations that alter amino acid sequences, creating truly foreign targets that escape the immune tolerance mechanisms that eliminated reactivity against self-antigens during normal T-cell development. As emphasized in a 2026 Nature Communications review by Nune Markosyan and Robert Vonderheide, this distinction between self-antigens and neoantigens addresses a critical immunological limitation of previous cancer vaccines. The field now faces the critical question of whether precisely targeted neoantigen immunity can translate into durable clinical benefits across diverse cancer types.

Pancreatic ductal adenocarcinoma (PDAC) has proven resistant to immunotherapies that succeeded against other cancers. New research published in Cell reveals a promising combination strategy: pairing KRAS inhibitors with 21h10, a synthetic mimic of the immune cytokine IL-21. In mouse models, this combination produced durable tumor remissions by activating CD4 T cells—contrary to conventional approaches focusing on CD8 T cells—which recruited macrophages to eliminate tumors. The KRAS inhibitor creates a therapeutic window by shrinking tumors and reducing immunosuppressive signals, allowing 21h10 to drive potent anti-tumor responses. Remarkably, complete tumor clearance occurred without requiring CD8 T cells or MHC class I expression on tumor cells. Instead, 21h10 expanded Th1-polarized CD4 T cells that produced interferon-gamma. Critically, T cells from human pancreatic tumors demonstrated responsiveness to 21h10 in laboratory experiments, suggesting this mechanism may translate to patients. This research challenges existing immunotherapy paradigms and offers a novel approach to extend KRAS inhibitor benefits in pancreatic cancer, a historically difficult-to-treat malignancy.

AstraZeneca's ETCAMAH (camizestrant) has received FDA accelerated approval in combination with CDK4/6 inhibitors (abemaciclib, palbociclib, or ribociclib) for treating hormone receptor-positive, HER2-negative advanced or metastatic breast cancer with emergent ESR1 mutations detected during aromatase inhibitor and CDK4/6 inhibitor therapy. The approval follows results from the pivotal SERENA-6 Phase III trial, presented at the 2025 American Society of Clinical Oncology Annual Meeting and published in The New England Journal of Medicine. The trial demonstrated that the combination reduced disease progression or death risk by 56 percent compared to standard aromatase inhibitor therapy with CDK4/6 inhibitors, with a hazard ratio of 0.44 and median progression-free survival of 16.0 versus 9.2 months. This approval represents AstraZeneca's tenth FDA authorization this year and fourth in breast cancer, marking the first first-line medicine of its type utilizing circulating tumor DNA detection. The combination addresses approximately one-third of advanced breast cancer patients developing ESR1 mutations, enabling earlier therapeutic intervention before clinical progression and potentially improving patient outcomes and quality of life.